Lilly(Eli) & Company

NYSE: LLY
$748.01
-$1.91 (-0.3%)
Closing Price on November 22, 2024

LLY Articles

Dicerna Pharmaceuticals and Eli Lilly are partnering up in a global licensing and research collaboration focused on the discovery, development and commercialization of potential new medicines in the...
The October 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
The September 28 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks decreased.
The top analyst upgrades, downgrades and initiations seen on Friday included Carbonite, Cleveland-Cliffs, Conoco, Costco, EA, Eli Lilly, HP, PepsiCo and Roku.
The September 14 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
With the markets at all-time highs, it is prime season for initial public offerings and companies can get more bang for their buck. There were a couple major IPOs this week that lived up to the hype...
Eli Lilly spin-off Elanco Animal Health made a strong entrance to the market on Thursday.
The August 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Eli Lilly spin-off Elanco Animal Health has amended its filing with the SEC regarding its initial public offering.
The August 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks was mixed.
Big Pharma is looking good for investors in the second half of 2018. That's the message from the research team at Bank of America Merrill Lynch.
The July 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Animal health company Elanco Animal Health has filed with the SEC regarding its initial public offering.
The top analyst upgrades, downgrades and other research calls from Wednesday include Broadcom, China Life, Crocs, Eli Lilly, Lockheed Martin, Philip Morris, Rio Tinto and Spotify.
The July 13 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.